Mirum Pharmaceuticals Inc... (MIRM)
Mirum Pharmaceuticals Statistics
Share Statistics
Mirum Pharmaceuticals has 49.01M shares outstanding. The number of shares has increased by 2.98% in one year.
| Shares Outstanding | 49.01M |
| Shares Change (YoY) | 2.98% |
| Shares Change (QoQ) | 0.62% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 39.12M |
| Failed to Deliver (FTD) Shares | 3.13K |
| FTD / Avg. Volume | 0.6% |
Short Selling Information
The latest short interest is 6.65M, so 13.85% of the outstanding shares have been sold short.
| Short Interest | 6.65M |
| Short % of Shares Out | 13.85% |
| Short % of Float | 17.36% |
| Short Ratio (days to cover) | 15.35 |
Valuation Ratios
The PE ratio is -22.34 and the forward PE ratio is -92.94. Mirum Pharmaceuticals's PEG ratio is 0.42.
| PE Ratio | -22.34 |
| Forward PE | -92.94 |
| PS Ratio | 5.83 |
| Forward PS | 2.1 |
| PB Ratio | 8.71 |
| P/FCF Ratio | 210.57 |
| PEG Ratio | 0.42 |
Enterprise Valuation
Mirum Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.23B.
| EV / Earnings | -13.97 |
| EV / Sales | 3.65 |
| EV / EBITDA | -25.09 |
| EV / EBIT | -14.03 |
| EV / FCF | 131.67 |
Financial Position
The company has a current ratio of 3.1, with a Debt / Equity ratio of 1.41.
| Current Ratio | 3.1 |
| Quick Ratio | 2.93 |
| Debt / Equity | 1.41 |
| Total Debt / Capitalization | 58.48 |
| Cash Flow / Debt | 0.03 |
| Interest Coverage | -6.12 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on capital (ROIC) is -16.31%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -16.31% |
| Revenue Per Employee | $1,046,236.02 |
| Profits Per Employee | $-273,111.8 |
| Employee Count | 322 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 3.64 |
Taxes
| Income Tax | 1.03M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 83.44% in the last 52 weeks. The beta is 1.04, so Mirum Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | 83.44% |
| 50-Day Moving Average | 47.93 |
| 200-Day Moving Average | 41.91 |
| Relative Strength Index (RSI) | 47.52 |
| Average Volume (20 Days) | 521.04K |
Income Statement
In the last 12 months, Mirum Pharmaceuticals had revenue of 336.89M and earned -87.94M in profits. Earnings per share was -1.85.
| Revenue | 336.89M |
| Gross Profit | 255.25M |
| Operating Income | -87.61M |
| Net Income | -87.94M |
| EBITDA | -48.97M |
| EBIT | -87.61M |
| Earnings Per Share (EPS) | -1.85 |
Balance Sheet
The company has 222.5M in cash and 317.76M in debt, giving a net cash position of -95.26M.
| Cash & Cash Equivalents | 222.5M |
| Total Debt | 317.76M |
| Net Cash | -95.26M |
| Retained Earnings | -644.18M |
| Total Assets | 670.75M |
| Working Capital | 266.24M |
Cash Flow
In the last 12 months, operating cash flow was 10.32M and capital expenditures -993K, giving a free cash flow of 9.33M.
| Operating Cash Flow | 10.32M |
| Capital Expenditures | -993K |
| Free Cash Flow | 9.33M |
| FCF Per Share | 0.2 |
Margins
Gross margin is 75.77%, with operating and profit margins of -26% and -26.1%.
| Gross Margin | 75.77% |
| Operating Margin | -26% |
| Pretax Margin | -25.8% |
| Profit Margin | -26.1% |
| EBITDA Margin | -14.54% |
| EBIT Margin | -26% |
| FCF Margin | 2.77% |
Dividends & Yields
MIRM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.01% |
| FCF Yield | 0.41% |
Analyst Forecast
The average price target for MIRM is $66, which is 43.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $66 |
| Price Target Difference | 43.2% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 4 |